Emergent BioSolutions (EBS) Misses Q3 EPS by $2.71
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 +2.04%
Revenue Growth %: +32.0%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +32.0%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of ($0.36), $2.71 worse than the analyst estimate of $2.35. Revenue for the quarter came in at $329 million versus the consensus estimate of $486.84 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
